Acutus Medical Inc

OTC Pink - Current Information:AFIBUnited States

Yesterday

Show headlines and story abstract

• -- Earnings Flash (AFIB) ACUTUS MEDICAL Posts Q1 Continuing Operations Revenue $3.6M, from 23 hours ago by MT Newswires

  23 hours ago by MT Newswires
  Companies Mentioned: AFIB
  04:04 PM EDT, 05/09/2024 (MT Newswires) -- ...

• Acutus Medical Reports First Quarter 2024 Financial Results, from 23 hours ago by Dow Jones

  23 hours ago by Dow Jones
  Companies Mentioned: AFIB
  ------------ ----------- Total other (expense) income, net (1,480) 992 ------------ ----------- Loss from continuing operations before income taxes (2,055) (4,280) Income tax expense -- -- ------------ ----------- Net loss from continuing operations (2,055) (4,280) Discontinued operations: Income (loss) from discontinued operations before taxes 445 (12,035) Income tax expense - discontinued operations (10) -- ------------ ----------- Income (loss) from discontinued operations 435 (12,035) ------------ ----------- Net loss (1,620) (16,315) Other comprehensive income (loss) Unrealized gain on marketable securities -- 12 Foreign currency translation adjustment -- 59 ------------ ----------- Comprehensive loss $ (1,620) $ (16,244) ============ =========== Net (loss) earnings per share, basic and diluted Net loss - continuing operations $ (0.07) $ (0.15) ============ =========== Net income (loss)- discontinued operations $ 0.01 $ (0.42) ============ =========== Net loss per common share $ (0.06) $ (0.57) Weighted average number of common shares outstanding, basic and diluted 29,693,926 28,764,444 Acutus Medical, Inc. Consolidated Statements of Cash Flows Three Months Ended March 31, -------------------------------------- 2024 2023 ------------------- ----------------- (in thousands) (unaudited) Cash flows from operating activities Net loss $ (1,620) $ (16,315) Less: (Gain) Loss from discontinued operations (435) 12,035 Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense 86 93 Non-cash stock-based compensation expense 202 586 Accretion of discounts on marketable securities, net (23) (527) Amortization of debt issuance costs 87 104 Amortization of operating lease right-of-use assets 178 164 Gain on sale of business, net (2,792) (1,207) Change in fair value of warrant liability 283 (1,446) Change in fair value of contingent consideration -- 200 Changes in operating assets and liabilities: Accounts receivable (819) (429) Inventory (1,610) (234) Employer retention credit receivable -- 2,141 Prepaid expenses and other current assets 117 713 Other assets -- -- Accounts payable 404 161 Accrued liabilities (891) (1,133) Operating lease liabilities (117) (201) Other long-term liabilities -- (1) ----------- ---------- Net cash used in operating activities - continuing operations (6,950) (5,296) Net cash used in operating activities - discontinued operations (9,979) (10,432) ----------- ---------- Net cash used in operating activities (16,929) (15,728) ----------- ---------- Cash flows from investing activities Proceeds from sale of business 7,300 17,000 Purchases of available-for-sale marketable securities -- (28,019) Maturities of available-for-sale marketable securities 1,750 26,500 Purchases of property and equipment (105) (25) ----------- ---------- Net cash provided by investing activities - continuing operations 8,945 15,456 Net cash provided by (used in) investing activities - discontinued operations 285 (207) ----------- ---------- Net cash provided by investing activities 9,230 15,249 ----------- ---------- Cash flows from financing activities Proceeds from the exercise of stock options -- 4 Net cash provided by financing activities - continuing operations -- 4 Net cash used in financing activities - discontinued operations (42) (217) ----------- ---------- Net cash used in financing activities (42) (213) ----------- ---------- Effect of exchange rate changes on cash, cash equivalents and restricted cash -- (779) Net change in cash, cash equivalents and restricted cash (7,741) (1,471) Cash, cash equivalents and restricted cash, at the beginning of the period 26,200 31,348 ----------- ---------- Cash, cash equivalents and restricted cash, at the end of the period $ 18,459 $ 29,877 =========== ========== Supplemental disclosure of cash flow information: Cash paid for interest 1,267 1,207 Supplemental disclosure of noncash investing and financing activities: Accounts receivable from sale of business 4,904 1,244 Change in unrealized (gain) loss on marketable securities (70) (12) Change in unpaid purchases of property and equipment -- (25)
  

• *DJ Acutus Medical 1Q Loss/Shr 6c >AFIB, from 23 hours ago by Dow Jones

  23 hours ago by Dow Jones
  Companies Mentioned: AFIB